Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation

Garderet, L.; Iacobelli, S.; Moreau, P.; Dib, M.; Caillot, D.; Niederwieser, D.; Masszi, T.; Fontan, J.; Michallet, M.; Gratwohl, A.; Milone, G.; Doyen, C.; Pegourie, B.; Hajek, R.; Casassus, P.; Kolb, B.; Chaleteix, C.; Hertenstein, B.; Onida, F.; Ludwig, H.; Vekemans, M.; Ketterer, N.; Daguenel, A.; Koenecke, C.; Gorin, N.; Harousseau, J.; de Witte, T.; Morris, C.; Gahrton, G.

doi:10.1038/bmt.2011.47

Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation / L. Garderet, S. Iacobelli, P. Moreau, M. Dib, D. Caillot, D. Niederwieser, T. Masszi, J. Fontan, M. Michallet, A. Gratwohl, G. Milone, C. Doyen, B. Pegourie, R. Hajek, P. Casassus, B. Kolb, C. Chaleteix, B. Hertenstein, F. Onida, H. Ludwig, M. Vekemans, N. Ketterer, A. Daguenel, C. Koenecke, N. Gorin, J. Harousseau, T. de Witte, C. Morris, G. Gahrton. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 46:1(2011), pp. S3-S3. [10.1038/bmt.2011.47]